Despite extensive evidence supporting semaglutides pleiotropic benefits 11 , randomized clinical trial data evaluating its effects on aging biomarkers remain absent
It also has benefits that extend beyond weight loss, including improvement of cholesterol levels, and decreasing blood pressure in those with high blood pressure and those with cardiovascular disorders
Additionally, nNOS-deficient mice exhibited reduced nitrotyrosine staining and hepatic necrosis [47]
A 4% incidence of anemia after one year on GLP-1 RAs was noted, which is roughly 1 in 25 patients
Current access options in the UK include: enrollment in Phase 3 clinical trials at UK sites, private prescriptions from compounding pharmacies (very limited availability), or research peptides
Ellerbrock I, Sandstrm A, Tour J, et al